MBOT: Microbot Medical, Inc. Long-Term Debt Volume

Graphic logo of Microbot Medical, Inc (MBOT)

The market valuation dynamics for Microbot Medical Inc. (MBOT) on the GURU.Markets platform, where the indicator stands at 0.00, are based on an innovation development cycle independent of macroeconomics, which transforms biotechnology into a defensive asset. Microbot Medical Inc. (MBOT) is developing a comprehensive suite of robotic microsystems for vascular interventions, where physician training on Liberty consoles creates a powerful barrier to entry for competitors. The integration of this platform ensures the precision of remote operations, establishing new standards for minimally invasive surgery.

MBOT Microbot Medical Inc.: Company Long-Term Debts in the range 07/04/2022 - 10/28/2026

Analytical breakdowns for Microbot Medical Inc.

- price and consensus price forecast:
Share Price microbotmedical.com|MBOT - Analyst Consensus Forecast
- market capitalization data:
Market Capitalization Microbot Medical|MBOT - Enterprise Value
- book capitalization data:
Accounting Value per Share Microbot Medical|MBOT - Book Capitalization|Market Capitalization to Book Value Ratio microbotmedical.com|MBOT - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Microbot Medical Inc.|MBOT - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Microbot Medical, Inc|MBOT - Company Aggregate Debts|Debts to Net Assets Microbot Medical|MBOT - Company Long-Term Debt|Company Short-Term Indebtedness Microbot Medical
General company analysis:microbotmedical.com (MBOT)
Mass-produced product of Microbot Medical, Inc

The indicator is calculated by aggregating all credit obligations with a maturity exceeding twelve months from the balance sheet liabilities. This metric determines the degree of debt load and the financial stability of the issuer in the face of future payments. For Microbot Medical Inc. (MBOT), this is a critical resource for financing clinical trials and obtaining FDA certifications. The dynamics of the business's long-term borrowed capital reflect the balance between medtech expansion and default risks.

Competitor analysis

Company Long-Term Indebtedness intuitive.com ISRG|Company Long-Term Debts DHR (Danaher)|BDX - Long-Term Debt Volume|STE (STERIS Corporation) - Company Long-Term Debts|West Pharma Corp (WST) - Company Long-Term Liabilities|BAX (Baxter International) - Company Long-Term Debts|Company Long-Term Debts MASI|Company Long-Term Debt Stevanato Group (STVN)|Company Long-Term Debt Teleflex Inc. TFX|Company Long-Term Liabilities Merit Medical Systems Inc|Company Long-Term Loans and Borrowings Nobel Biocare NVST|Company Long-Term Debts ICUI (ICU Medical, Inc.)|XRAY: Long-Term Debt Volume|Company Long-Term Debt LeMaitre Vascular|ATRC (AtriCure Inc) - Company Long-Term Indebtedness|STAA: Company Long-Term Debt|Long-Term Debt Volume niagenbioscience.com (NAGE)|Company Long-Term Liabilities ZimVie Inc.|Amount of Long-Term Liabilities ANGO (angiodynamics.com)|Company Long-Term Debt Cerus|TKNO - Company Long-Term Loans and Borrowings|Monogram Technologies Inc - Company Long-Term Liabilities|STSS: Company Long-Term Debts|INFU (infusystem.com) - Company Long-Term Debt|utahmed.com (UTMD) - Company Long-Term Liabilities|Company Long-Term Debts KRMD (KORU Medical Systems, Inc.)|Long-Term Debt NYXH|Company Long-Term Debt Pro-Dex Corp PDEX|Company Long-Term Indebtedness Zentek Corp ZTEK|Company Long-Term Liabilities Elutia Inc. (ELUT)|milestonescientific.com - Amount of Long-Term Liabilities|Company Long-Term Debt NXGL (NEXGEL)|RVP: Long-Term Debt Volume|HBIO (Harvard Bioscience, Inc.) - Company Long-Term Debt|Femasys Corporation (FEMY) - Company Long-Term Liabilities|MHUA: Company Long-Term Debts|Long-Term Debt Volume Predictive Oncology Corp|Company Long-Term Debts CJMB (Callan JMB Inc)|Company Long-Term Liabilities ATRI (Atrion Corp.)|Company Long-Term Debt NeuroMetrix Corp